A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

NCT05283837 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

268

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

BIOLOGICAL: Pertuzumab (ZRC-3277)
BIOLOGICAL: Pertuzumab (Perjeta®)

Sponsor

Zydus Lifesciences Limited